Profound Medical to Participate in Lake Street's Best Ideas Conference
TORONTO – Profound Medical Corp. (NASDAQ: PROF; TSX: PRN), a frontrunner in the creation of innovative medical devices, has announced its participation in one of the season's most awaited events: the Lake Street Capital Markets 8th Annual Best Ideas Growth Conference. This event is set to take place on September 12, 2024, in New York City.
Conference Highlights
This year's conference will include one-on-one meetings between the company's management team and investors. Although there won't be a webcast available, these meetings will offer a great opportunity for attendees to gain insights into Profound Medical’s growth strategy and its groundbreaking technologies.
Revolutionary Therapies from Profound Medical
As a commercial-stage medical device company, Profound Medical is dedicated to developing customizable and incision-free therapies. One of its standout products is the TULSA-PRO system, an advanced technology that combines real-time MRI guidance with robotically-driven transurethral ultrasound and sophisticated temperature feedback control. This state-of-the-art system allows for precise treatment of prostate diseases, making it accessible to patients with varying risk profiles.
Understanding the TULSA Procedure
The TULSA procedure is particularly significant for its ability to provide personalized treatment options tailored to each patient's needs. By leveraging real-time MRI for pinpoint accuracy, the system aims to minimize damage to surrounding tissues, helping to preserve urinary continence and sexual function during prostate treatments. The procedure is efficient, typically completed in a single session lasting just a few hours, with patients often experiencing minimal recovery time.
Expanding Horizons with Sonalleve
Alongside TULSA-PRO, Profound Medical is also advancing the Sonalleve system, which is designed for the non-invasive treatment of uterine fibroids and for alleviating palliative pain related to bone metastases. The technology has received CE marking in Europe and has been approved by the China National Medical Products Administration, positioning it as a significant player in the market. Plans are underway to further explore potential treatments, especially in the area of non-invasive abdominal cancer therapy.
Looking Ahead: Future Innovations
Profound Medical is focused on expanding the applications of both TULSA and Sonalleve technologies. Ongoing research aims to enhance current treatments and discover new opportunities where these innovative solutions can have a meaningful impact, particularly in oncology.
Get in Touch with Profound Medical
If you're interested in learning more about Profound Medical and its innovative offerings, please reach out to Stephen Kilmer, who oversees investor relations. You can contact him at 647.872.4849 or via email. Profound Medical is dedicated to pushing the boundaries of medical care, ensuring that patients receive cutting-edge, effective treatments without the complexities often associated with traditional methods.
Frequently Asked Questions
What is the purpose of the Lake Street Conference?
The conference serves as a platform for companies like Profound Medical to engage with investors and discuss their business strategies and innovations.
What are the key products of Profound Medical?
Profound Medical specializes in TULSA-PRO and Sonalleve, both offering innovative solutions for treating prostate diseases and uterine fibroids, respectively.
How does the TULSA procedure work?
The TULSA procedure employs real-time MRI guidance and ultrasound technology to accurately target and treat prostate tissue while safeguarding surrounding areas.
What approvals does Sonalleve hold?
Sonalleve is CE marked in Europe, has received approval in China, and holds a Humanitarian Device Exemption from the FDA for certain treatments.
Who can I contact for more information about Profound Medical?
For further information, you can reach out to Stephen Kilmer from investor relations via phone or email.
